DelveInsight’s “Cytomegalovirus (CMV) Infection - Market Insights, Epidemiology and Market Forecast-2023-EU5” Report provides an overview of the disease and market size of the CMV for the EU5 (France, Germany, Italy, Spain and United Kingdom) for 2013-2023. It also includes historical and forecast edepidemiological data for the CMV Prevalent, Diagnosed and Treatable Cases, CMV Patients among Transplants, Infants Patients at High Risk of CMV and HIV Patients at High Risk of CMV from 2013-2023.
According to DelveInsight, the total number of Diagnosed Cytomegalovirus (CMV) infection cases in France is expected to increase at a CAGR of 0.06% to 20,871 cases by 2023. In case of Germany it is expected to increase at a CAGR of 0.067% to 21,619 cases by 2023. In United Kingdom, the total number of Diagnosed Cytomegalovirus (CMV) infection cases is expected to increase at a CAGR of 0.061% to 14,417 cases by 2023 and in Spain is expected to increase at a CAGR of 0.029% to 12,810 cases in 2023. For Italy, it is expected to increase at a CAGR of 0.031% to 13,358 cases in 2023. CMV infection is most prevalent in Italy and least prevalent in Spain of the EU5.
As per DelveInsight’s estimation, the market size of Cytomegalovirus (CMV) infection shall reach to USD 50.2 Million in Italy, USD 213.3 Million in Germany, USD 142.3 Million in France, USD 62.8 Million in Spain and USD 63.8 Million in United Kingdom by the end of 2023. Italy has the lowest and Germany has the highest market size of the EU5.
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.
Scope
- Report covers the disease overview including pathophysiology, symptoms, diagnosis, disease management, and current treatment options.
- Marketed information including available prescription drugs.
- The Report also covers the detailed historical and forecasted epidemiological data covering Spain, Italy, United Kingdom, Germany, and France from 2013-2023.
- It also provides Market size of Cytomegalovirus (CMV) infection for Spain, Italy, United Kingdom, Germany, and France from 2013 and forecasted Market size to 2023.
'
Cytomegalovirus Infections
Disease Overview
Symptoms of cytomegalovirus (CMV) Infection
Etiology
Risk Factors
Pathogenesis of human cytomegalovirus
Pathophysiology of cytomegalovirus infection
Diagnosis
Treatment Algorithm for Cytomegalovirus Infections
Treatment for Congenital CMV Infection
Treatment of Ganciclovir resistant CMV
Treatment Guidelines
Recommendations for Treating Cytomegalovirus Infections
Disease Management
Epidemiology and Patient Population
Europe
Assumptions and Rationale
Italy
Total CMV Prevalent, Diagnosed and Treatable Cases
CMV Patients among Transplants
Infants Patients at High Risk of CMV
HIV Patients at High Risk of CMV
Spain
Total CMV Prevalent, Diagnosed and Treatable Cases
CMV Patients among Transplants
Infants Patients at High Risk of CMV
HIV Patients at High Risk of CMV
United Kingdom
Total CMV Prevalent, Diagnosed and Treatable Cases
CMV Patients among Transplants
Infants Patients at High Risk of CMV
HIV Patients at High Risk of CMV
Germany
Total CMV Prevalent, Diagnosed and Treatable Cases
CMV Patients among Transplants
Infants Patients at High Risk of CMV
HIV Patients at High Risk of CMV
France
Total CMV Prevalent, Diagnosed and Treatable Cases
CMV Patients among Transplants
Infants Patients at High Risk of CMV
HIV Patients at High Risk of CMV
Unmet Medical Needs
Marketed Products
Valcyte (Valganciclovir hydrochloride)
Advantages & Disadvantages
Product Profile
Efficacy
Safety
Side effects of Drug
SWOT Analysis
FOSCAVIR (foscarnet sodium)
Advantages & Disadvantages
Product Profile
Efficacy
Safety
Side effects of Drug
SWOT Analysis
CytoGam (Cytomegalovirus Immune Globulin Intravenous-Human)
Advantages & Disadvantages
Product Profile
Efficacy
Safety
Side effects of Drug
SWOT Analysis
CytoTect CP
Advantages & Disadvantages
Product Profile
Efficacy
Safety
Side effects of Drug
SWOT Analysis
Valtrex (Valacyclovir hydrochloride)
Advantages & Disadvantages
Product Profile
Efficacy
Safety
Side effects of Drug
SWOT Analysis
Emerging Products Analysis
Emerging Therapies
1. Approved Products
Cytovir CMV: Cell Medica Ltd.
Product Description
Research and Development
Product Development Activities
2. Pipeline Products (Phase III)
CytoTect CP 70: Biotest AG.
Product Description
Advantages & Disadvantages
Research and Development
Product Development Activities
Letermovir: Merck & Co.
Product Description
Advantages & Disadvantages
Research and Development
Product Development Activities
Brincidofovir: Chimerix Inc.
Product Description
Advantages & Disadvantages
Research and Development
Product Development Activities
ASP0113: Astellas Pharma Global Development, Inc.
Product Description
Advantages & Disadvantages
Research and Development
Product Development Activities
Human Cytomegalovirus Immune Globulin: CSL Behring
Product Description
Advantages & Disadvantages
Research and Development
Product Development Activities
Europe Market Size
Italy
Germany
France
Spain
United Kingdom
Market Drivers
Market Barriers
Appendix
Report Methodology
Consulting Services
Disclaimer
About DelveInsight
Table 1: Total CMV Prevalent, Diagnosed and Treatable Cases for Italy (2013-2023)
Table 2: CMV Patients among Transplants in Italy (2013-2023)
Table 3: Infants Patients at High Risk of CMV in Italy (2013-2023)
Table 4: HIV Patients at High Risk of CMV in Italy (2013-2023)
Table 5: Total CMV Prevalent, Diagnosed and Treatable Cases for Spain (2013-2023)
Table 6: CMV Patients among Transplants in Spain (2013-2023)
Table 7: Infants Patients at High Risk of CMV in Spain (2013-2023)
Table 8: HIV Patients at High Risk of CMV in Spain (2013-2023)
Table 9: Total CMV Prevalent, Diagnosed and Treatable Cases for United Kingdom (2013-2023)
Table 10: CMV Patients among Transplants in United Kingdom (2013-2023)
Table 11: Infants Patients at High Risk of CMV in United Kingdom (2013-2023)
Table 12: HIV Patients at High Risk of CMV in United Kingdom (2013-2023)
Table 13: Total CMV Prevalent, Diagnosed and Treatable Cases for Germany (2013-2023)
Table 14: CMV Patients among Transplants in Germany (2013-2023)
Table 15: Infants Patients at High Risk of CMV in Germany (2013-2023)
Table 16: HIV Patients at High Risk of CMV in Germany (2013-2023)
Table 17: Total CMV Prevalent, Diagnosed and Treatable Cases for France (2013-2023)
Table 18: CMV Patients among Transplants in France (2013-2023)
Table 19: Infants Patients at High Risk of CMV in France (2013-2023)
Table 20: HIV Patients at High Risk of CMV in France (2013-2023)
Table 21: Total Market size of Cytomegalovirus (CMV) Infection USD, Million(2013-2023)
Table 22: Total Market size of Cytomegalovirus (CMV) Infection USD, Million(2013-2023)
Table 23: Total Market size of Cytomegalovirus (CMV) Infection USD, Million(2013-2023)
Table 24: Total Market size of Cytomegalovirus (CMV) Infection USD, Million(2013-2023)
Table 25: Total Market size of Cytomegalovirus (CMV) Infection USD, Million (2013-2023)
